Download Patient and Scientific Review Board – Biographies of

Patient and Scientific Review Board – Biographies of Members
January 2017
Professor Dr. Dr. Thomas Bieber (Germany)
Professor Bieber studied medicine (MD) and biology (PhD) in France. He trained in dermatology, allergy,
dermatopathology and occupational dermatology. He also trained in drug regulatory affairs (master degree;
MDRA) and got special expertise in legal aspects of drug development and cosmetics.
Since 1997, Prof. Bieber is chair of the department of dermatology and allergy at the University of Bonn, Germany.
He was vice-dean and then dean of the medical faculty. Besides clinical dermatology and allergy, his scientific
focus is in the pathophysiology of atopic dermatitis and in tolerance mechanisms. He is co- founder and speaker
of the Center of Translational Medicine (CTM), a joint research program between the Medical Faculty of the
University of Bonn and the German Federal Institute for Drugs and Medical Devices (BfArM).
He was recipient of many awards and is member or honorary member of several national and international
societies as well as of the German National Academy of Sciences. He authored more than 440 papers and 100
book chapters. He edited/authored several books on atopic dermatitis and more recently on personalized
medicine. He is chief-editor of ALLERGY the journal of the EAACI.
Relationship to LEO Pharma
Dr. Bieber has been investigator for a LEO Pharma sponsored clinical trial. He has also supported dermatology
research by his membership in an advisory board and as lecturer.
Julie Block (US)
Julie Block, President and Chief Executive Officer of the National Eczema Association since 2010, has dedicated
her career to the non-profit sector, and for the past several years, to patient-health advocacy.
Julie's extensive non-profit management, strategy and development experience stems from leadership positions in
education, medical technology, and the arts. At Harvard Medical School, she directed a variety of programs and
new initiatives, including the launch of a new AIDS research centre. Throughout her career, Julie has continued
her involvement with causes she is passionate about as a volunteer including the American Cancer Society Relay
for Life, the Susan G. Komen Breast Cancer Foundation, and Very Special Arts for children with special needs.
The immediate past-president of the Coalition of Skin Diseases, Julie is an active member of multiple national
groups focused on skin diseases in the U.S. -the American Academy of Dermatology Atopic Dermatitis Guidelines
Committee, Expert Resource, and Pruritus Work groups; the National Institute of Arthritis, Musculoskeletal and
Skin Coalition; and, the Friends of the National Institute for Environmental Health Sciences Coalition. She serves
on the LEO Pharma Patient and Scientific Review Board, and a variety of other ad- hoc pharmaceutical industry
initiatives. She recently served on the NIAID Food Allergy Guidelines Committee and the Expert Panel on the
Peanut Allergy Addendum to the Food Allergy Guidelines. She is a past member of the National Health Council
Membership Committee. She has been invited to share her expertise in eczema patient advocacy at national and
international conferences including the Cochran Annual Meeting on Comparative Effective Research, BIO
International Convention, National Institutes of Health Roundtable events, and most recently, the International
Symposium on Atopic Dermatitis, and the First Israeli Symposium on Atopic Dermatitis.
ALL LEO TRADEMARKS MENTIONED
BELONG TO THE LEO GROUP
Julie holds a Bachelor in Arts in Liberal Arts, and received her education at University of California at
Santa Barbara, San Diego State University and Harvard University extension.
2/3
Relationship to LEO Pharma
LEO Pharma and Julie Block have previously been in discussion on how LEO Pharma can support the work of the
National Eczema Association, and on the development of a Quality Care™ module for eczema.
Sally Hollis (UK)
Sally Hollis is currently Head of Statistical Consulting at Phastar, a specialist CRO; and has an honorary position
at the University of Manchester as Professor of Clinical Trials.
Sally has over 25 years’ experience in a wide variety of roles in medical statistics in the NHS, academia and the
pharmaceutical industry. During 12 years at AstraZeneca, she held a number of statistical leadership roles in drug
development, across phase II and III, and lifecycle management. She is currently co-lead of a Clinical Trial Data
Sharing special interest group of statisticians in industry and academia.
Sally has collaborated in research in a range of therapeutic areas, including trauma, diabetes, dermatology,
oncology, rheumatology and respiratory diseases. She has been statistical editor of several journals, including
Diabetic Medicine and Annals of Clinical Biochemistry and of the Cochrane Skin Group.
No previous relationship with LEO Pharma
Professor Dr. Guy Meyer (France)
Guy Meyer is currently Clinical Professor of Respiratory Medicine at Paris Descartes University and attending
physician in the department of respiratory and intensive care medicine at Hôpital Europeen Georges Pompidou in
Paris.
Dr. Meyer received his MD degree at Paris VII University in 1986 and trained in respiratory medicine and intensive
Care at Hôpital Laennec in Paris. He received training in basic science research at University Paris VII and
INSERM. Faculty appointments include Paris Descartes University where he was promoted from assistant lecturer
to professor of respiratory medicine in 1999.
Dr. Meyer is involved in clinical research on the diagnosis, epidemiology and treatment of pulmonary embolism
and on the relationship between thromboembolism and cancer. He is the principal investigator of the PEITHO trial
on the role of fibrinolysis in intermediate-risk pulmonary embolism. He has been involved in several large
multi-centre studies on the diagnosis and treatment of pulmonary embolism, including two large multi-centre
studies assessing the effectiveness of multi-detector computed tomography angiography, the ADJUST-PE study
assessing an age-adjusted D-dimer cut-off for excluding pulmonary embolism, the PREPIC-2 trial assessing the
role of retrievable vena cava filters in patients with pulmonary embolism and the PADIS-PE trial assessing the role
of a prolonged anticoagulant treatment in patients with a first unprovoked episode of pulmonary embolism. He is
the principal investigator of the TILT study addressing the effect of low-molecular weight heparin on the survival of
patients with completely resected non-small cell lung cancer. Dr. Meyer is the chairman of INNOVTE a large
network of clinical sites and research units involved in research on venous thromboembolism in France. He is the
author or the co-author of about 150 publications indexed in Medline.
Relationship to LEO Pharma
3/3
Dr. Meyer has previously been investigator and member of the steering committee of the CATCH trial, sponsored
by LEO Pharma. Currently, he acts as an investigator in investigator-initiated trials; not sponsored by LEO Pharma
but investigating a LEO Pharma product.
Katherine Murphy (UK)
Katherine joined The Patients Association in 2003 as Head of Communications having come from a background in
Nursing. She was appointed Chief Executive in 2008. As Chief Executive, Katherine has been at the forefront of
most of the recent campaigns at The Patients Association, and has initiated a number of other high profile
initiatives that have featured largely in the media including:






The Care Campaign
Patient Stories
Malnutrition
Pain
Dignity and Compassion
Reform of the NHS Complaints System
Katherine is a dedicated and tireless campaigner with a very strong interest in the rights and responsibilities of the
patient and a true patient advocate. She is passionate about making sure the patient's voice is central to every
decision and that the patient voice is heard and translated into genuine quality improvement for all. The
co-creation of policy and partnership decision making must be present in all health and social care encounters.
Katherine continues to set the strategic direction of the Patients Association; during her time with the organisation
Katherine, has worked with the Department of Health, NHS England, Care Quality Commission, Cabinet office,
Medicines and Healthcare products Regulatory Agency (MHRA), Royal College of Nursing, Nursing and Midwifery
Council and all the of Medical Royal Colleges and other health and social care regulators.
Katherine sits on many Committees and Boards always representing the views of the patient and making sure the
rhetoric from politicians is translated into reality for patients and the public.
For the past 18 months Katherine has dedicated her time and energy working in partnership with many NHS
Directors of Patient Experience, cascading good practice through joint conferences on the patient journey in the
hope that this will translate to good patient experience and outcomes.
Katherine was a member of the Prime Minister’s Nursing Care Quality Forum and is a member of the Equality and
Diversity Forum.
In 2011 Katherine was nominated by the London Evening Standard as one of the capital’s 1000 most influential
people
No previous relationship with LEO Pharma